These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?
Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively. Argus raised Amgen’s target to $460 from $375 and maintained a ‘Buy’ rating, according to The Fly. Amgen’s Q2 revenue increased 10% from a year earlier to $10.1 billion, while … Read more